Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD4054 plus carboplatin and paclitaxel in platinum-sensitive recurrent ovarian cancer
2008-006068-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing Zibotentan + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Apr 2009; status: completed.
02
Drugs
zibotentan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2008-006068-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006068-12.